Chris Karp
Director, Global Health Discovery & Translational Sciences @ Bill & Melinda Gates Foundation
Seattle, United States
Chris Karp is a Series B investor at Bill & Melinda Gates Foundation in Seattle focused on Medical and Health Care. Chris Karp - Director, Global Health Discovery & Translational Sciences @ Bill & Melinda Gates Foundation
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Chris Karp invests in
Stages Chris Karp invests in
Countries Chris Karp invests in
Investment Focus
Industry
- Medical 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Immunocore
|
Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100,entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems. Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies. | $130M / Series B / Mar 02, 2020 | |
|
Immunocore
|
Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100,entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems. Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies. | $40M / Series B |
Co-Investors
General Atlantic
2 deals together
CCB International
1 deal together
Eli Lilly
1 deal together
JDRF T1D Fund
1 deal together
Rock Springs Capital
1 deal together
RTW Investments
1 deal together
About Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a grant-making foundation that supports initiatives in education, world health and population, and community giving in the Pacific Northwest. In its local region, the foundation promotes strategies and programs that help low income families.The Bill & Melinda Gates Foundation was co-founded by BillGates and Melinda Gates in 2000 and is based in Seattle, Washington, with regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom. Its trustees are Bill and Melinda Gates, and Warren Buffett.
Bill & Melinda Gates Foundation Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bill Gates
Co-Chairman of the Board
|
|||
Bill Gates
Co-Chairman of the Board
|
|||
Brian Arbogast
Director of the Water, Sanitation & Hygiene Program
|
|||
|
Chris Karp
Director, Global Health Discovery & Translational Sciences
|
|||
Dan Hartman
Director, Integrated Development; Interim Director, Malaria. Global Health
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chris Karp invest in?
Chris Karp invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Chris Karp last invest?
The most recent investment recorded for Chris Karp closed in Mar 2020. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
